Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Prognostic implications of cumulative dosing in total therapy 3.

Barlogie B, Crowley J.

Blood. 2012 Oct 18;120(16):3383-5. doi: 10.1182/blood-2012-05-426809. No abstract available. Erratum in: Blood. 2013 Mar 7;121(10):1924.

2.

Histone deacetylase inhibitors in multiple myeloma.

Pratt G.

Lancet Oncol. 2013 Oct;14(11):1038-9. doi: 10.1016/S1470-2045(13)70425-X. Epub 2013 Sep 19. No abstract available.

PMID:
24055413
3.

New hope for relapsed and refractory multiple myeloma.

Leleu X.

Lancet Oncol. 2013 Oct;14(11):1028-9. doi: 10.1016/S1470-2045(13)70399-1. Epub 2013 Sep 3. No abstract available.

PMID:
24007745
4.

Panobinostat for the treatment of multiple myeloma.

Rajkumar SV.

Lancet Oncol. 2014 Oct;15(11):1178-9. doi: 10.1016/S1470-2045(14)70443-7. Epub 2014 Sep 18. No abstract available.

PMID:
25242046
5.

Panobinostat to revert bortezomib resistance.

Moreau P.

Blood. 2013 Oct 3;122(14):2292-3. doi: 10.1182/blood-2013-08-522417. No abstract available.

6.

Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma".

Harrison SJ, Quach H, Spencer A, Prince HM.

Haematologica. 2015 Sep;100(9):e379. doi: 10.3324/haematol.2015.128470. No abstract available.

7.

Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma.

Kraut EH, Young D, Farag S, James AG, Solove RJ.

Leuk Res. 2005 Oct;29(10):1233-4. Epub 2005 Apr 1. No abstract available.

PMID:
16111541
8.

[Carfilzomib in multiple myeloma relapses].

Bay JO.

Bull Cancer. 2015 Feb;102(2):116. French. No abstract available.

PMID:
25874287
9.

The "Next Big Thing" in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design-Between the Lines.

Ruggeri K, Maguire Á, Cook G.

JAMA Oncol. 2016 Nov 1;2(11):1405-1406. doi: 10.1001/jamaoncol.2016.1782. No abstract available.

PMID:
27355621
10.

Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma.

Chanan-Khan A, Miller KC.

Leuk Lymphoma. 2005 Jul;46(7):1103-4. No abstract available.

PMID:
16019567
11.

Evidence does not support clinically significant lenalidomide-CCI-779 interaction via P-glycoprotein.

Chen N, Kasserra C, Kumar G, Palmisano M.

J Clin Oncol. 2012 Jan 20;30(3):340-1; author reply 341-2. doi: 10.1200/JCO.2011.39.4163. Epub 2011 Dec 12. No abstract available.

PMID:
22162571
12.

Muscular Relapse in a Patient With Multiple Myeloma.

Waheed S, Zhu H, Waheed MA, Kumar M, Barlogie B.

J Clin Oncol. 2015 Dec 1;33(34):e125-9. doi: 10.1200/JCO.2013.51.6450. Epub 2014 Apr 28. No abstract available.

PMID:
24778395
13.

[Current aspects of treatment of multiple myeloma].

Tribalto M, Avvisati G, Cantonetti M, Catalano G, Giovangrossi P, Masi M, Petrucci MT, Venditti A, Papa G.

Ann Ital Med Int. 1988 Jul-Sep;3(3):193-202. Review. Italian. No abstract available.

PMID:
3152856
14.

[Multiple myeloma -- therapy].

Jung W, Zettl F, Schroers R.

Dtsch Med Wochenschr. 2005 Feb 11;130(6):283-6; quiz 287-90. German. No abstract available.

PMID:
15692903
15.
16.

Novel combination approaches for myeloma.

Lonial S, Nooka AK.

Hematology Am Soc Hematol Educ Program. 2015;2015:286-93. doi: 10.1182/asheducation-2015.1.286. No abstract available.

17.

Advances in treatment for relapses and refractory multiple myeloma.

Richards T, Weber D.

Med Oncol. 2010 Jun;27 Suppl 1:S25-42. doi: 10.1007/s12032-009-9407-5. Epub 2010 Mar 6. Review.

PMID:
20213220
18.

Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.

Guglielmelli T, Bringhen S, Rrodhe S, Gay F, Cavallo F, Berruti A, Montefusco V, Piro E, Benevolo G, Petrucci MT, Caravita T, Offidani M, Corradini P, Boccadoro M, Saglio G, Palumbo A.

Eur J Cancer. 2011 Apr;47(6):814-8. doi: 10.1016/j.ejca.2010.12.026. Epub 2011 Feb 18.

PMID:
21334196
19.

Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide.

Mele G, Giannotta A, Pinna S, Loseto G, Coppi MR, Brocca CM, Melpignano A, Quarta G.

Leuk Lymphoma. 2010 May;51(5):937-40. doi: 10.3109/10428191003695660. No abstract available.

PMID:
20350279
20.

Novel agents for relapsed and/or refractory multiple myeloma.

Thomas SK, Richards TA, Weber DM.

Cancer J. 2009 Nov-Dec;15(6):485-93. doi: 10.1097/PPO.0b013e3181c51cba. Review.

PMID:
20010168

Supplemental Content

Support Center